Literature DB >> 19817779

Insulin intensification strategies in type 2 diabetes: when one injection is no longer sufficient.

A J Garber1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19817779     DOI： 10.1111/j.1463-1326.2009.01139.x

Source DB:  PubMed          Journal:  Diabetes Obes Metab        ISSN： 1462-8902            Impact factor:   6.577


× No keyword cloud information.
  6 in total

Review 1.  Insulin degludec and insulin aspart: novel insulins for the management of diabetes mellitus.

Authors:  Stephen Atkin; Zeeshan Javed; Gregory Fulcher
Journal:  Ther Adv Chronic Dis       Date:  2015-11       Impact factor: 5.091

2.  Evidence-based clinical use of insulin premixtures.

Authors:  Marcos Antônio Tambascia; Márcia Nery; Jorge Luiz Gross; Mariana Narbot Ermetice; Carolina Piras de Oliveira
Journal:  Diabetol Metab Syndr       Date:  2013-09-06       Impact factor: 3.320

Review 3.  Expert Group Recommendations on the Effective Use of Bolus Insulin in the Management of Type 2 Diabetes Mellitus.

Authors:  Rajeev Chawla; Jagat Jyoti Mukherjee; Manoj Chawla; Alok Kanungo; Meenakshi Sundaram Shunmugavelu; Ashok Kumar Das
Journal:  Med Sci (Basel)       Date:  2021-05-28

4.  Distinct Prandial and Basal Glucose-Lowering Effects of Insulin Degludec/Insulin Aspart (IDegAsp) at Steady State in Subjects with Type 1 Diabetes Mellitus.

Authors:  Tim Heise; Leszek Nosek; Carsten Roepstorff; Suresh Chenji; Oliver Klein; Hanne Haahr
Journal:  Diabetes Ther       Date:  2014-06-03       Impact factor: 2.945

5.  Treatment intensification with an insulin degludec (IDeg)/insulin aspart (IAsp) co-formulation twice daily compared with basal IDeg and prandial IAsp in type 2 diabetes: a randomized, controlled phase III trial.

Authors:  H W Rodbard; B Cariou; T R Pieber; L A Endahl; J Zacho; J G Cooper
Journal:  Diabetes Obes Metab       Date:  2016-01-11       Impact factor: 6.577

6.  The co-formulation of insulin degludec and insulin aspart lowers fasting plasma glucose and rates of confirmed and nocturnal hypoglycaemia, independent of baseline glycated haemoglobin levels, disease duration or body mass index: A pooled meta-analysis of phase III studies in patients with type 2 diabetes.

Authors:  Martin Haluzík; Greg Fulcher; Thomas R Pieber; Lars Bardtrum; Deniz Tutkunkardas; Helena W Rodbard
Journal:  Diabetes Obes Metab       Date:  2018-03-25       Impact factor: 6.577
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.